Leica Biosystems and Indica Labs Expand Digital Pathology-Powered Diagnostics in the USA with Aperio HALO AP DX Software Launch

Delivering a Complete Clinical Digital Pathology Ecosystem Combining Aperio HALO AP DX Image Management System and High‑Performance Aperio GT 450 DX Scanner

Vista, CA, and Albuquerque, NM, March 31, 2026 – Leica Biosystems, a Danaher company and a global leader in anatomic and digital pathology solutions, and Indica Labs, a global leader in artificial intelligence (AI)-powered digital pathology software, launches Aperio HALO AP DX image management system designed for use with the Aperio GT 450 DX scanner. Together, the Aperio HALO AP DX software and the Aperio GT 450 DX scanner provide a complete, integrated clinical digital pathology solution supporting on‑screen diagnostics across routine pathology workflows in the USA.

The Aperio HALO AP DX software is a pathologist‑driven, browser‑based image management platform that enables efficient access to whole slide images generated by the Aperio GT 450 DX scanner. When used together, the solution delivers a seamless digital workflow—integrating patient data, digital slides, annotations, and reports into a single, ergonomic, case‑centric environment—designed to support primary diagnosis, tumor boards, consultations, and second opinions.

This launch represents the latest development following the strategic partnership agreement between Leica Biosystems and Indica Labs announced in January 2025. It delivers a complete solution for clinical diagnostics in the USA, and underscores the companies’ continued innovation and commitment to delivering meaningful, customer‑focused digital pathology solutions.

"This latest clinical offering extends our comprehensive digital pathology ecosystem, and is designed to improve collaboration, efficiency, and access to pathology expertise—supporting faster, more reliable diagnoses and ultimately helping ensure patients receive the right care at the right time," said Naveen Chandra, Vice President and General Manager of Digital Pathology at Leica Biosystems. “Pathologists need digital solutions that work as a complete system, not isolated components. The combination of the Aperio GT 450 DX scanner with Aperio HALO AP DX image management software delivers an integrated clinical digital pathology solution designed around real‑world diagnostic workflows."

Indica Labs CEO Steven Hashagen commented, “This latest clinical offering marks an important milestone in our partnership with Leica Biosystems. The Aperio HALO AP DX software builds on the recognized strength of Indica Labs’ clinically focused image management platform and the Aperio GT 450 DX scanner, both recognized for their performance and leadership in recent KLAS reports. Combining these powerful solutions provides a complete, seamless solution for pathologists—helping them work more efficiently, collaborate more effectively, and deliver confident diagnostic decisions in routine clinical practice.”

The introduction of the Aperio HALO AP DX software underscores the shared vision of Leica Biosystems and Indica Labs to advance digital pathology through pathologist‑centric design, interoperability, and scalable enterprise deployment, helping laboratories meet growing diagnostic demands while maintaining high standards of quality and efficiency.

For In Vitro Diagnostic Use

About Leica Biosystems
Leica Biosystems is a cancer diagnostics company and a global leader in anatomic and digital pathology solutions. The company offers a comprehensive product range for each step in the pathology process, from sample preparation and staining to imaging and reporting. As the only company to own the full workflow from biopsy to diagnosis, Leica Biosystems is uniquely positioned to break down the barriers between each step. The company’s mission of “Advancing Cancer Diagnostics, Improving Lives” is at the heart of its corporate culture. Leica Biosystems is proud to be a Danaher Corporation subsidiary.

About Indica Labs
Indica Labs, the global leader in AI-powered digital pathology, is redefining medicine with pathology platforms supporting life science discovery, translational research, clinical workflows, and companion diagnostic development. HALO platforms integrate image management and quantitative image analysis to deliver standardized, reproducible tissue-based analysis at every stage of the translational journey.

About Danaher
Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher's advanced science and technology - and proven ability to innovate - help enable faster, more accurate diagnoses and help reduce the time and cost needed to sustainably discover, develop and deliver life-changing therapies. Focused on scientific excellence, innovation and continuous improvement, our approximately 63,000 associates worldwide help ensure that Danaher is improving quality of life for billions of people today, while setting the foundation for a healthier, more sustainable tomorrow. Explore more at www.danaher.com.